Literature DB >> 28794279

Nasopharyngeal infection by Streptococcus pyogenes requires superantigen-responsive Vβ-specific T cells.

Joseph J Zeppa1, Katherine J Kasper1, Ivor Mohorovic1, Delfina M Mazzuca1, S M Mansour Haeryfar1,2,3,4, John K McCormick5,3,4.   

Abstract

The globally prominent pathogen Streptococcus pyogenes secretes potent immunomodulatory proteins known as superantigens (SAgs), which engage lateral surfaces of major histocompatibility class II molecules and T-cell receptor (TCR) β-chain variable domains (Vβs). These interactions result in the activation of numerous Vβ-specific T cells, which is the defining activity of a SAg. Although streptococcal SAgs are known virulence factors in scarlet fever and toxic shock syndrome, mechanisms by how SAgs contribute to the life cycle of S. pyogenes remain poorly understood. Herein, we demonstrate that passive immunization against the Vβ8-targeting SAg streptococcal pyrogenic exotoxin A (SpeA), or active immunization with either wild-type or a nonfunctional SpeA mutant, protects mice from nasopharyngeal infection; however, only passive immunization, or vaccination with inactive SpeA, resulted in high-titer SpeA-specific antibodies in vivo. Mice vaccinated with wild-type SpeA rendered Vβ8+ T cells poorly responsive, which prevented infection. This phenotype was reproduced with staphylococcal enterotoxin B, a heterologous SAg that also targets Vβ8+ T cells, and rendered mice resistant to infection. Furthermore, antibody-mediated depletion of T cells prevented nasopharyngeal infection by S. pyogenes, but not by Streptococcus pneumoniae, a bacterium that does not produce SAgs. Remarkably, these observations suggest that S. pyogenes uses SAgs to manipulate Vβ-specific T cells to establish nasopharyngeal infection.

Entities:  

Keywords:  Streptococcus pyogenes; T cells; infection; nasopharynx; superantigen

Year:  2017        PMID: 28794279      PMCID: PMC5617250          DOI: 10.1073/pnas.1700858114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  58 in total

Review 1.  Toxic shock syndrome and bacterial superantigens: an update.

Authors:  J K McCormick; J M Yarwood; P M Schlievert
Journal:  Annu Rev Microbiol       Date:  2001       Impact factor: 15.500

2.  Streptococcus pyogenes causing toxic-shock-like syndrome and other invasive diseases: clonal diversity and pyrogenic exotoxin expression.

Authors:  J M Musser; A R Hauser; M H Kim; P M Schlievert; K Nelson; R K Selander
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

3.  Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group.

Authors:  R Kaul; A McGeer; A Norrby-Teglund; M Kotb; B Schwartz; K O'Rourke; J Talbot; D E Low
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

Review 4.  Mechanisms of Bacterial Colonization of the Respiratory Tract.

Authors:  Steven J Siegel; Jeffrey N Weiser
Journal:  Annu Rev Microbiol       Date:  2015       Impact factor: 15.500

Review 5.  The global burden of group A streptococcal diseases.

Authors:  Jonathan R Carapetis; Andrew C Steer; E Kim Mulholland; Martin Weber
Journal:  Lancet Infect Dis       Date:  2005-11       Impact factor: 25.071

6.  Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes.

Authors:  K H Lee; K W Wucherpfennig; D C Wiley
Journal:  Nat Immunol       Date:  2001-06       Impact factor: 25.606

7.  Differential effects of staphylococcal toxic shock syndrome toxin-1 on B cell apoptosis.

Authors:  M F Hofer; K Newell; R C Duke; P M Schlievert; J H Freed; D Y Leung
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

8.  Invasive M1T1 group A Streptococcus undergoes a phase-shift in vivo to prevent proteolytic degradation of multiple virulence factors by SpeB.

Authors:  Ramy K Aziz; Michael J Pabst; Arthur Jeng; Rita Kansal; Donald E Low; Victor Nizet; Malak Kotb
Journal:  Mol Microbiol       Date:  2004-01       Impact factor: 3.501

Review 9.  Disease manifestations and pathogenic mechanisms of Group A Streptococcus.

Authors:  Mark J Walker; Timothy C Barnett; Jason D McArthur; Jason N Cole; Christine M Gillen; Anna Henningham; K S Sriprakash; Martina L Sanderson-Smith; Victor Nizet
Journal:  Clin Microbiol Rev       Date:  2014-04       Impact factor: 26.132

10.  Bacterial superantigens promote acute nasopharyngeal infection by Streptococcus pyogenes in a human MHC Class II-dependent manner.

Authors:  Katherine J Kasper; Joseph J Zeppa; Adrienne T Wakabayashi; Stacey X Xu; Delfina M Mazzuca; Ian Welch; Miren L Baroja; Malak Kotb; Ewa Cairns; P Patrick Cleary; S M Mansour Haeryfar; John K McCormick
Journal:  PLoS Pathog       Date:  2014-05-29       Impact factor: 6.823

View more
  22 in total

1.  Group A Streptococcus Infection of the Nasopharynx Requires Proinflammatory Signaling through the Interleukin-1 Receptor.

Authors:  Doris L LaRock; Raedeen Russell; Anders F Johnson; Shyra Wilde; Christopher N LaRock
Journal:  Infect Immun       Date:  2020-09-18       Impact factor: 3.441

2.  Bacterial Superantigens Expand and Activate, Rather than Delete or Incapacitate, Preexisting Antigen-Specific Memory CD8+ T Cells.

Authors:  Courtney E Meilleur; Christine M Wardell; Tina S Mele; Jimmy D Dikeakos; Jack R Bennink; Hong-Hua Mu; John K McCormick; S M Mansour Haeryfar
Journal:  J Infect Dis       Date:  2019-04-08       Impact factor: 5.226

3.  Shocking superantigens promote establishment of bacterial infection.

Authors:  Nikolai Siemens; Anna Norrby-Teglund
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-12       Impact factor: 11.205

4.  Streptococcus pyogenes genes that promote pharyngitis in primates.

Authors:  Luchang Zhu; Randall J Olsen; Stephen B Beres; Matthew Ojeda Saavedra; Samantha L Kubiak; Concepcion C Cantu; Leslie Jenkins; Andrew S Waller; Zhizeng Sun; Timothy Palzkill; Adeline R Porter; Frank R DeLeo; James M Musser
Journal:  JCI Insight       Date:  2020-06-04

5.  Recurrent group A Streptococcus tonsillitis is an immunosusceptibility disease involving antibody deficiency and aberrant TFH cells.

Authors:  Jennifer M Dan; Colin Havenar-Daughton; Kayla Kendric; Rita Al-Kolla; Kirti Kaushik; Sandy L Rosales; Ericka L Anderson; Christopher N LaRock; Pandurangan Vijayanand; Grégory Seumois; David Layfield; Ramsey I Cutress; Christian H Ottensmeier; Cecilia S Lindestam Arlehamn; Alessandro Sette; Victor Nizet; Marcella Bothwell; Matthew Brigger; Shane Crotty
Journal:  Sci Transl Med       Date:  2019-02-06       Impact factor: 17.956

6.  Physicochemical characterisation, immunogenicity and protective efficacy of a lead streptococcal vaccine: progress towards Phase I trial.

Authors:  Manisha Pandey; Jessica Powell; Ainslie Calcutt; Mehfuz Zaman; Zachary N Phillips; Mei Fong Ho; Michael R Batzloff; Michael F Good
Journal:  Sci Rep       Date:  2017-10-23       Impact factor: 4.379

7.  Immunotherapy targeting the Streptococcus pyogenes M protein or streptolysin O to treat or prevent influenza A superinfection.

Authors:  Andrea L Herrera; Christopher Van Hove; Mary Hanson; James B Dale; Rodney K Tweten; Victor C Huber; Diego Diel; Michael S Chaussee
Journal:  PLoS One       Date:  2020-06-23       Impact factor: 3.240

8.  The conserved mosaic prophage protein paratox inhibits the natural competence regulator ComR in Streptococcus.

Authors:  Lauren Mashburn-Warren; Steven D Goodman; Michael J Federle; Gerd Prehna
Journal:  Sci Rep       Date:  2018-11-08       Impact factor: 4.379

9.  Streptococcal superantigen-induced expansion of human tonsil T cells leads to altered T follicular helper cell phenotype, B cell death and reduced immunoglobulin release.

Authors:  F J Davies; C Olme; N N Lynskey; C E Turner; S Sriskandan
Journal:  Clin Exp Immunol       Date:  2019-03-13       Impact factor: 4.330

Review 10.  Playing With Fire: Proinflammatory Virulence Mechanisms of Group A Streptococcus.

Authors:  Shyra Wilde; Anders F Johnson; Christopher N LaRock
Journal:  Front Cell Infect Microbiol       Date:  2021-07-06       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.